Enabling In Vivo CAR-T: Targeted Engineering, High-Titer LVV Manufacturing, and T-Cell-Specific Delivery

Traditional LVVs used for ex vivo CAR-T require significant engineering to function effectively as an in vivo CAR-T therapeutic. In this joint webinar, uBriGene Biosciences and Senlang Biotechnology will share their complementary technologies and successful collaboration on the clinical development of in vivo CAR-T.

 
uBriGene will present the proprietary  uVivo™ LVV platform:
  • Targeted envelope engineering of Cocal-G fusogen to overcome native Cocal tropism and enable T-cell-directed delivery
  • Proprietary CD7 nanobody T-cell binder
  • High-titer LVV manufacturing to address viral packaging and production bottlenecks
  • CMC data for safety, potency, target specificity, and QCs

Senlang will present its proprietary T-cell binder platform and the clinical development of its lead asset:

  • T-cell-specific binder engineering for targeted cell engagement
  • Binder optimization to enhance selective T-cell targeting
  • Collaboration with uBriGene to advance targeted in vivo CAR-T development
The webinar will conclude with a fireside chat exploring the challenges, opportunities, and future directions of in vivo CAR-T.